[DOI] [PMC free article] [PubMed] [Google Scholar] [13].Sodhi M., Rezaeianzadeh R., Kezouh A., and Etminan M., Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss., JAMA, Oct
CDI specialists should review for documentation gaps: Common Pitfall Many coders assign only a Z89 acquired absence code and miss the underlying etiology
E08 Diabetes Mellitus Due to Underlying Condition E09 Drug or Chemical Induced Diabetes Mellitus E10 Type 1 Diabetes Mellitus E11 Type 2 Diabetes Mellitus (Most Commonly Used) E13 Other Specified Diabetes Mellitus E13 applies to post-pancreatectomy diabetes, MODY, neonatal diabetes, and other forms not captured by E08 to E11
One tiny oversight, and the claim comes bouncing faster than you can say denial, and denials
Brain Sci
Consent for publication Not applicable